Related Experiment Video
Updated: Apr 27, 2026

Assessing Urinary Tract Junction Obstruction Defects by Methylene Blue Dye Injection
Published on: October 12, 2017
Association of urinary transforming growth factor-β1 with the ureteropelvic junction obstruction
Alireza Merrikhi1, Emad Bahraminia1
1Department of Pediatrics, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
Insights
Urinary transforming growth factor-beta 1 (TGF-β1) levels are significantly higher in children with ureteropelvic junction obstruction (UPJO). This biomarker shows promise for confirming UPJO diagnosis in pediatric patients.
Area of Science:
- Pediatric Nephrology
- Urology
- Biomarker Discovery
Background:
- Ureteropelvic junction obstruction (UPJO) is a common congenital anomaly in children.
- Accurate diagnosis and monitoring of UPJO are crucial for preserving renal function.
- Identifying reliable biomarkers for UPJO is an ongoing area of research.
Purpose of the Study:
- To compare urinary transforming growth factor-beta 1 (TGF-β1) levels in children diagnosed with UPJO versus healthy controls.
- To investigate the correlation between urinary TGF-β1 levels and the severity of UPJO and renal injury.
Main Methods:
- A case-control study involving 25 children with UPJO and 25 matched healthy peers.
- Urine samples were collected to measure urinary TGF-β1 using ELISA.
- Renal function was assessed by glomerular filtration rate (GFR), and UPJO severity by ultrasonography.
Main Results:
- Children with UPJO exhibited significantly higher mean urinary TGF-β1 levels (87.1 pg/ml) compared to controls (30.5 pg/ml).
- Urinary TGF-β1 levels correlated with the degree of UPJO, with Grade IV hydronephrosis showing the highest levels (P = 0.0001).
- Mean GFR was slightly lower in the UPJO group (112.4) than in the control group (123.29).
Conclusions:
- Urinary TGF-β1 serves as a potential biomarker for confirming UPJO in pediatric cases.
- Further research is warranted to establish specific diagnostic cut-off points for TGF-β1 in UPJO.
- Biomarker analysis can aid in the non-invasive assessment of UPJO severity and potential renal impact.
Background:
We aimed to compare the level of urinary transforming growth factor-beta 1 (TGF-β1) in children with ureteropelvic junction obstruction (UPJO) with the normal peers.
Materials And Methods:
In this case-control study, we enrolled children with UPJO and matched normal peers. Sterile urine was collected from the subjects and urinary TGF-β1 was measured by ELISA method. Also, degree of the UPJO and the magnitude of the renal injury were assessed by ultrasonography and measuring glomerular filtration rate (GFR), respectively. Study variables were then compared between the study groups regarding the level of urinary TGF-β1.
Results:
A total of 25 children with UPJO (age = 7.4 ± 4.5 years; male = 16) were compared with 25 healthy peers (age = 6.8 ± 5.6 years; male = 16). Mean GFR in the UPJO and the control group were 112.4 ± 10.1 and 123.29 ± 4.4, respectively. Mean urinary TGF-β1 in the UPJO group was 87.1 ± 12.6 pg/ml vs 30.5 ± 14.5 pg/ml in the control group. The level of urinary TGF-β1 was significantly associated with the degree of TGF-β1 and patients with grade IV hydronephrosis had the highest level of urinary TGF-β (P = 0.0001).
Conclusion:
Based on our findings, biomarkers such as TGF-β1 can successfully be used for confirming UPJO. However, further studies are needed to determine the proper cut point for diagnosis confirmation.
More Related Videos
04:37Unilateral Ureteral Obstruction Model for Investigating Kidney Interstitial Fibrosis
Published on: April 25, 2025
06:39Technical Modification of the Terminal Ureter During Total Transperitoneal Laparoscopic Nephroureterectomy for Upper Urinary Tract Urothelial Carcinoma
Published on: November 22, 2019
Related Concept Videos
Urinary Tract Calculi II: Pathophysiology and Clinical Manifestations
Urinary Tract Calculi I: Introduction
Urinary Tract Calculi III: Medical Management
Ureters
Urinary Tract Calculi VI: Surgical Management
Acute Kidney Injury II: Pathophysiology